Bringing the Oncology Community Together

Dr. Hudis on Promising Treatment Strategies in TNBC

Clifford A. Hudis, MD
Published Online: Thursday, October 17, 2013
Clifford A. Hudis, MD, ASCO president, chief, Breast Cancer Medicine Service, attending physician, Memorial Sloan-Kettering Cancer Center, discusses the challenges and recent advancements of treating patients with triple-negative breast cancer (TNBC).

Although TNBC has always been understood and recognized, it continues to be a focal point of research and represents one of the remaining prominent challenges in breast cancer, Hudis says. While all types and stages breast cancer has challenges, physicians and researchers have failed to make large strides with targeted therapies in TNBC compared to hormone receptor-positive disease and human epidermal growth factor receptor-positive disease.

Hudis says researchers struggle with TNBC because they are unsure if it is a single entity or if it is another collection of subtypes of breast cancer that might be amenable to targeting. Drugs must also be developed to address the totality of TNBC or at least change outcomes for a number of identifiable subsets.

But advancements are being made in the field. Hudis says there is a focus on the small proportion of patients with TNBC that express the androgen receptor (AR). AR-positive TNBC may be a subtype of the disease where researchers can focus on one type of therapy -- a non-toxic hormone treatment.

If researchers can detect the presence of AR in a triple-negative tumor using a conventional Dako IHC stain, bicalutamide can be used to give these patients a 20% chance of long-term disease stabilization, Hudis says.

Although this treatment is only temporary and not a cure, Hudis says, it is an important advance in TNBC.
Related Articles
Phase III Clinical Trials in HER2-Positive Breast Cancer
Expert panelists explore several large clinical trials examining therapies for patients with HER2-positive breast cancer that are currently ongoing or have recently completed.
Experts Support Broader Pertuzumab Use in HER2-Positive Breast Cancer
The recent approval of pertuzumab as part of a combination neoadjuvant treatment for patients with early-stage breast cancer has paved the way for wider use of the regimen in preoperative settings.
New ASCO Guideline Expands Recommendation for SLN Biopsy Use in Early Stage Breast Cancer
An updated guideline from ASCO regarding the use of sentinel lymph node (SLN) biopsy in early stage breast cancer supports the use of the procedure over axillary lymph node dissection (ALND) in a larger group of patients than previously recommended.
Most Popular Right Now
More Reading
External Resources

American Journal of Managed Care
Pharmacy Times
Physicians' Education Resource
Physician's Money Digest
Specialty Pharmacy Times
OncLive Resources

OncLive TV
Oncology Nurses
Web Exclusives

About Us
Advisory Board
Contact Us
Forgot Password
Privacy Policy
Terms & Conditions
Intellisphere, LLC
666 Plainsboro Road
Building 300
Plainsboro, NJ 08536
P: 609-716-7777
F: 609-716-4747

Copyright OncLive 2006-2014
Intellisphere, LLC. All Rights Reserved.